Merck & Co. Pauses Enrollment Of Oral Islatravir In PrEP Studies As Bad News Mounts
Executive Summary
Merck has already paused other studies testing the potential first-in-class NRTTI and is adding additional monitoring of lymphocyte and CD4+ T-cell assessments.
You may also be interested in...
Merck & Co Resumes Islatravir HIV Studies After Safety Concerns, But Abandons PrEP Approach
After a nine-month US FDA-imposed pause, Merck is relaunching its studies of islatravir with a lower dose, while also abandoning its use in PrEP studies.
Merck's Gefapixant CRL Dashes Hopes For Another Near-Term Growth Driver
The US FDA issued a complete response letter for the P2X3 receptor antagonist for the treatment of refractory chronic cough, requesting more efficacy data.
Q4 Earnings Preview: Setting The Tone For 2022 (Part 1)
Biopharma will outline its growth goals for 2022 over the coming weeks, with J&J, Novartis, AbbVie, Merck, Roche, Biogen and Lilly among the first to report.